An observational study in Acute Respiratory Distress Syndrome, sponsored by Southeast University, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Southeast University, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Respiratory Distress Syndrome by Southeast University, China — 10 open to participants now, 10 under way, 2 of them phase 3. Respiratory Distress Syndrome · Southeast University, China.
Among the 24 studies in Respiratory Distress Syndrome by Southeast University, China, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2026, is one of 13 observational ones, and was the 19th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →10 of the 24 studies in Respiratory Distress Syndrome by Southeast University, China are open now, in 1 country. Recruiting first, the newest first:
Southeast University, China · Sites in China
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 19+
By country, each count listing its studies:
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 93 across the 11 interventional studies, 134 across the 13 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Southeast University, China is the lead sponsor of 169 studies on the registry; 46 are open to participants now.
3 of the studies in Respiratory Distress Syndrome by Southeast University, China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07528196Phase 3Southeast University, ChinaStudy of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome | 2027-06 |
| NCT07289711Southeast University, ChinaValidation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study | 2026-12-31 |
| NCT06919484Southeast University, ChinaThe Physiological Effect of RCexp on Ventilation/Perfusion Distribution | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Respiratory Distress Syndrome by Southeast University, China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute respiratory distress syndrome (ARDS) is a major cause of mortality in intensive care units. Prone position ventilation (PPV) is an important component of ARDS management and has been shown to reduce mortality in patients with moderate-to-severe ARDS. However, substantial heterogeneity exists in treatment response to PPV. Previous studies suggest that lung morphology-focal versus non-focal patterns based on chest CT-may influence responses to ventilatory strategies, but whether lung morphology modifies the effect of PPV remains unclear. In addition, the benefits and safety of PPV in patients with acute brain injury (ABI) complicated by ARDS are uncertain. Although PPV improves oxygenation, it may impair cerebral venous drainage and increase intracranial pressure, raising concerns about its use in ABI patients. Evidence from randomized trials in this population is limited and excludes patients with more severe hypoxemia or elevated intracranial pressure.
Furthermore, the optimal duration and termination criteria for PPV are not well established. While PPV improves alveolar recruitment and reduces ventilator-induced lung injury, prolonged PPV may lead to excessive sedation exposure and PPV-related complications. Identifying the appropriate timing to discontinue PPV may help balance clinical benefits and potential harms.This study is a prospective, multicenter registry enrolling patients with moderate-to-severe ARDS. The objectives are: (1) To determine whether lung morphology can guide individualized PPV strategies; (2) To evaluate the effectiveness and safety of PPV in patients with ARDS complicated by acute brain injury; (3) To investigate the optimal timing for termination of PPV through target trial emulation methods.In addition to these core objectives, the study will include other exploratory aims.
Moderate-to-severe ARDS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.Age ≥ 18 years 2. Moderate-to-severe ARDS requiring invasive mechanical ventilation, defined as:
Exclusion Criteria:
1.Refusal of by the patient's legally authorized representative
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Prone position ventilation
Patients underwent prone positioning while receiving invasive mechanical ventilation
60-day mortality
The proportion of patients who are died within 60 days
Time frame: From inclusion to 28 days
28-day mortality
The proportion of patients who are died within 28 days
Time frame: From inclusion to 28 days
Ventilator-free days at 28 days
Days alive without endotracheal intubation and invasive mechanical ventilation
Time frame: From inclusion to 28 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jan 2029, 36 months later.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →